The Effect of Melatonin and Vitamin C on COVID-19

Not Applicable

Completed

• Conditions: Covid19; SARS-CoV Infection
• Interventions: Dietary Supplement: Placebo; Dietary Supplement: melatonin; Dietary Supplement: Vitamin C; Other: Symptom Survey

• Registration Number: NCT04530539
• Lead Sponsor: Lancaster General Hospital

Brief Summary

This is a double-blind placebo controlled trial that seeks to evaluate the impact of melatonin and vitamin C on symptoms and outcomes of patients with COVID-19.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-08-26
• Study First Submitted QC: 2020-08-26
• Study First Posted: 2020-08-28
• Study Start: 2020-10-05
• Status Verified: 2022-08
• Primary Completion: 2022-08-11
• Study Completion: 2022-08-11
• Last Update Submitted: 2022-08-16
• Last Update Posted: 2022-08-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 122

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental- Melatonin	Symptom Survey	Patients will receive melatonin
Control	Placebo	Patients will receive placebo
Experimental- Melatonin	melatonin	Patients will receive melatonin
Experimental- Vit C	Vitamin C	Patients will receive vitamin C
Experimental- Vit C	Symptom Survey	Patients will receive vitamin C
Control	Symptom Survey	Patients will receive placebo

Primary Outcome Measures

Name	Time	Method
Symptom Severity	14 days	Symptom severity will be tracked electronically

Secondary Outcome Measures

Name	Time	Method
Symptom progression	14 days	Determine symptom course of those with moderate or severe symptoms

Trial Locations

Locations (1)

Lancaster General Health; 🇺🇸 Lancaster, Pennsylvania, United States